Stryker (1SYK) Stock Forecast & Price Target

1 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

1SYK Analyst Ratings

Strong Buy

16 Buy

2 Hold

0 Sell

Based on 18 analysts giving stock ratings to

Stryker

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

1SYK Stock 12 Month Forecast

Average Price Target

€330.11

▲(13.79% Upside)

Based on 18 Wall Street analysts offering 12 month price targets for Stryker in the last 3 months. The average price target is €330.11 with a high forecast of €390.30 and a low forecast of €291.66. The average price target represents a 13.79% change from the last price of €290.10.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"258":"€258","391":"€391","291.25":"€291.3","324.5":"€324.5","357.75":"€357.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":390.3033225,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€390.30</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":330.1052793529411,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€330.11</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":291.65523,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€291.66</span>\n  </div></div>","useHTML":true}}],"tickPositions":[258,291.25,324.5,357.75,391],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,281.1,289.5002555769231,297.9005111538462,306.3007667307692,314.7010223076923,323.1012778846154,331.5015334615385,339.9017890384615,348.3020446153846,356.7023001923077,365.1025557692308,373.50281134615386,381.90306692307695,{"y":390.3033225,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,281.1,284.8696368733032,288.63927374660636,292.40891061990953,296.17854749321265,299.9481843665158,303.717821239819,307.48745811312216,311.25709498642533,315.0267318597285,318.7963687330316,322.5660056063348,326.33564247963795,{"y":330.1052793529411,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,281.1,281.9119407692308,282.72388153846157,283.53582230769234,284.3477630769231,285.1597038461539,285.97164461538466,286.7835853846154,287.59552615384615,288.4074669230769,289.2194076923077,290.03134846153847,290.84328923076924,{"y":291.65523,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":326.092,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":323.518,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":305.796,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":308.177,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":317.9,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":298.503,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":310.837,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":329.537,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":283.947,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":269.984,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":259.213,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":277,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":281.1,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€390.30

Average Price Target€330.11

Lowest Price Target€291.66

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Ryan Zimmerman

BTIG

€307.1

Buy

5.86%

Upside

Reiterated

08/27/26

Analysts Offer Insights on Healthcare Companies: Connect Biopharma Holdings (NASDAQ: CNTB) and Stryker (NYSE: SYK)

Joanne Wuensch

Citi

€330.26→€342.27

Buy

17.98%

Upside

Reiterated

08/14/26

Citi Sticks to Its Buy Rating for Stryker (SYK)

Travis Steed

Bank of America Securities

€17.16→€325.97

Buy

12.36%

Upside

Reiterated

08/11/26

Bank of America Securities Sticks to Its Buy Rating for Stryker (SYK)

Robbie Marcus

J.P. Morgan

€300.23

Buy

3.49%

Upside

Reiterated

08/04/26

Stryker (SYK) Receives a Buy from J.P. Morgan

David Turkaly

Citizens JMP

€377.44→€343.12

Buy

18.28%

Upside

Reiterated

08/03/26

Stryker price target lowered to $400 from $440 at CitizensStryker price target lowered to $400 from $440 at Citizens

Steven Lichtman

William Blair

―

Buy

―

Reiterated

07/31/26

Stryker: Analyst Sees Share Weakness as a Chance to Buy into a Durable High-Growth Medtech Leader

Jayson Bedford

Raymond James

€328.54→€317.39

Buy

9.41%

Upside

Reiterated

07/31/26

Stryker price target lowered to $370 from $383 at Raymond JamesStryker price target lowered to $370 from $383 at Raymond James

Richard Newitter

Truist Financial

€283.08→€291.66

Hold

0.54%

Upside

Reiterated

07/31/26

Truist Financial Sticks to Its Hold Rating for Stryker (SYK)

Michael Matson

Needham

€358.56

Buy

23.60%

Upside

Reiterated

07/31/26

Analysts Conflicted on These Healthcare Names: Roivant Sciences (NASDAQ: ROIV), Neurocrine (NASDAQ: NBIX) and Stryker (NYSE: SYK)

Mathew Blackman

TD Cowen

€304.52

Hold

4.97%

Upside

Assigned

07/31/26

Analysts Conflicted on These Healthcare Names: Alnylam Pharma (NASDAQ: ALNY), Stryker (NYSE: SYK) and Bicycle Therapeutics (NASDAQ: BCYC)

Kendall Au

RBC Capital

€373.15→€360.28

Buy

24.19%

Upside

Reiterated

07/31/26

Stryker (SYK) Receives a Buy from RBC Capital

Vik Chopra

BMO Capital

€316.53

Buy

9.11%

Upside

Reiterated

07/31/26

BMO Capital Remains a Buy on Stryker (SYK)

Matthew O'Brien

Piper Sandler

€360.28→€334.55

Buy

15.32%

Upside

Reiterated

07/31/26

Piper Sandler Remains a Buy on Stryker (SYK)

Patrick Wood

UBS

€325.97→€343.12

Buy

18.28%

Upside

Upgraded

07/28/26

Analysts Are Bullish on These Healthcare Stocks: The Ensign Group (ENSG), Stryker (SYK)

David Toung

Argus Research

€300.23→€317.39

Buy

9.41%

Upside

Assigned

07/09/26

Stryker price target raised to $370 from $350 at ArgusStryker price target raised to $370 from $350 at Argus

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Ryan Zimmerman

BTIG

€307.1

Buy

5.86%

Upside

Reiterated

08/27/26

Analysts Offer Insights on Healthcare Companies: Connect Biopharma Holdings (NASDAQ: CNTB) and Stryker (NYSE: SYK)

Joanne Wuensch

Citi

€330.26→€342.27

Buy

17.98%

Upside

Reiterated

08/14/26

Citi Sticks to Its Buy Rating for Stryker (SYK)

Travis Steed

Bank of America Securities

€17.16→€325.97

Buy

12.36%

Upside

Reiterated

08/11/26

Bank of America Securities Sticks to Its Buy Rating for Stryker (SYK)

Robbie Marcus

J.P. Morgan

€300.23

Buy

3.49%

Upside

Reiterated

08/04/26

Stryker (SYK) Receives a Buy from J.P. Morgan

David Turkaly

Citizens JMP

€377.44→€343.12

Buy

18.28%

Upside

Reiterated

08/03/26

Stryker price target lowered to $400 from $440 at CitizensStryker price target lowered to $400 from $440 at Citizens

Steven Lichtman

William Blair

―

Buy

―

Reiterated

07/31/26

Stryker: Analyst Sees Share Weakness as a Chance to Buy into a Durable High-Growth Medtech Leader

Jayson Bedford

Raymond James

€328.54→€317.39

Buy

9.41%

Upside

Reiterated

07/31/26

Stryker price target lowered to $370 from $383 at Raymond JamesStryker price target lowered to $370 from $383 at Raymond James

Richard Newitter

Truist Financial

€283.08→€291.66

Hold

0.54%

Upside

Reiterated

07/31/26

Truist Financial Sticks to Its Hold Rating for Stryker (SYK)

Michael Matson

Needham

€358.56

Buy

23.60%

Upside

Reiterated

07/31/26

Analysts Conflicted on These Healthcare Names: Roivant Sciences (NASDAQ: ROIV), Neurocrine (NASDAQ: NBIX) and Stryker (NYSE: SYK)

Mathew Blackman

TD Cowen

€304.52

Hold

4.97%

Upside

Assigned

07/31/26

Analysts Conflicted on These Healthcare Names: Alnylam Pharma (NASDAQ: ALNY), Stryker (NYSE: SYK) and Bicycle Therapeutics (NASDAQ: BCYC)

Kendall Au

RBC Capital

€373.15→€360.28

Buy

24.19%

Upside

Reiterated

07/31/26

Stryker (SYK) Receives a Buy from RBC Capital

Vik Chopra

BMO Capital

€316.53

Buy

9.11%

Upside

Reiterated

07/31/26

BMO Capital Remains a Buy on Stryker (SYK)

Matthew O'Brien

Piper Sandler

€360.28→€334.55

Buy

15.32%

Upside

Reiterated

07/31/26

Piper Sandler Remains a Buy on Stryker (SYK)

Patrick Wood

UBS

€325.97→€343.12

Buy

18.28%

Upside

Upgraded

07/28/26

Analysts Are Bullish on These Healthcare Stocks: The Ensign Group (ENSG), Stryker (SYK)

David Toung

Argus Research

€300.23→€317.39

Buy

9.41%

Upside

Assigned

07/09/26

Stryker price target raised to $370 from $350 at ArgusStryker price target raised to $370 from $350 at Argus

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

ODTXOdyssey Therapeutics, Inc.

AVBPArriVent BioPharma, Inc.

BTSGBrightSpring Health Services, Inc.

GPCRStructure Therapeutics, Inc. Sponsored ADR

AMLXAmylyx Pharmaceuticals Inc

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Stryker

3 Months

Robbie MarcusJ.P. Morgan

Success Rate

15/19 ratings generated profit

Average Return

+4.16%

Copying Robbie Marcus's trades and holding each position for 3 Months would result in 78.95% of your transactions generating a profit, with an average return of +4.16% per trade.

1 Year

Larry BiegelsenWells Fargo

Success Rate

20/26 ratings generated profit

Average Return

+10.85%

Copying Larry Biegelsen's trades and holding each position for 1 Year would result in 76.92% of your transactions generating a profit, with an average return of +10.85% per trade.

2 Years

Jeff JohnsonRobert W. Baird

Success Rate

25/30 ratings generated profit

Average Return

+19.25%

Copying Jeff Johnson's trades and holding each position for 2 Years would result in 83.33% of your transactions generating a profit, with an average return of +19.25% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

1SYK Analyst Recommendation Trends

Rating

Apr 26

May 26

Jun 26

Jul 26

Aug 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 1SYK has received 26 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. 1SYK average Analyst price target in the past 3 months is 330.11.

Each month's total comprises the sum of three months' worth of ratings.

1SYK Financial Forecast

1SYK Earnings Forecast

Next quarter’s earnings estimate for 1SYK is €3.10 with a range of €2.97 to €3.28. The previous quarter’s EPS was €3.19. 1SYK beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 1SYK has Performed in-line its overall industry.

1SYK Sales Forecast

Next quarter’s sales forecast for 1SYK is €5.77B with a range of €5.69B to €5.84B. The previous quarter’s sales results were €5.69B. 1SYK beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 1SYK has Performed in-line its overall industry.

1SYK Stock Forecast FAQ

What is IT:1SYK’s average 12-month price target, according to analysts?

Based on analyst ratings, Stryker Corp’s 12-month average price target is 330.11.

What is IT:1SYK’s upside potential, based on the analysts’ average price target?

Stryker Corp has 13.79% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Stryker Corp a Buy, Sell or Hold?

Stryker Corp has a consensus rating of Strong Buy, which is based on 16 buy ratings, 2 hold ratings and 0 sell ratings.

What is Stryker Corp’s share price target?

The average share price target for Stryker Corp is 330.11. This is based on 18 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €390.30 ,and the lowest forecast is €291.66. The average share price target represents 13.79% Increase from the current price of €290.1.

What do analysts say about Stryker Corp?

Stryker Corp’s analyst rating consensus is a Strong Buy. This is based on the ratings of 18 Wall Streets Analysts.

How can I buy shares of Stryker Corp?

To buy shares of IT:1SYK, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Stryker (1SYK) Stock Forecast & Price Target

1SYK Analyst Ratings

1SYK Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Stryker

1SYK Analyst Recommendation Trends

1SYK Financial Forecast

1SYK Earnings Forecast

1SYK Sales Forecast

1SYK Stock Forecast FAQ

Detailed List of Analyst Forecasts